| Bioactivity | YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity[1]. |
| Invitro | YLT-11 (0-1 µM; 48 h) 以剂量依赖性方式降低 p-PLK4 的表达[1]。YLT-11 (0-0.5 µM; 0-48 h) 诱导细胞凋亡和细胞周期停滞在 G2/M 期[1]。 Cell Proliferation Assay[1] Cell Line: |
| In Vivo | YLT-11 (30、90 mg/kg；口服；每日一次，持续 20 天) 在小鼠体内显示出抗癌活性[1]。 Animal Model: |
| Name | YLT-11 |
| Formula | C24H24N6O |
| Molar Mass | 412.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lei Q, et al. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death Dis. 2018 Oct 18;9(11):1066. |